A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. - Sven J. van der Lee, van der Lee Sj, Iris Jansen, Luca Kleineidam, Erik van den Akker, Isabel Hernández, Conway Oj, Kristel R. van Eijk, Najada Stringa, Anna Zettergren, Javier Simon-Sanchez, Carrasquillo Mm, Alberto Lleó, Henrik Zetterberg, Adela Orellana - Dissemin

Language
Login

Published in

Springer, Acta Neuropathologica, 2(138), p. 237-250, 2019

DOI: 10.1007/s00401-019-02026-8

SSRN Electronic Journal, 2018

DOI: 10.2139/ssrn.3307650

Links

Tools

Export citation

Search in Google Scholar

A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.

Journal article published in 2018 by Sven J. van der Lee, van der Lee Sj, Iris Jansen, Luca Kleineidam, Erik van den Akker, Isabel Hernández, Conway Oj, Kristel R. van Eijk, Najada Stringa, Anna Zettergren, Javier Simon-Sanchez, Carrasquillo Mm, Alberto Lleó, Henrik Zetterberg, Adela Orellana and other authors.

This paper is made freely available by the publisher.

This paper is made freely available by the publisher.

Full text: Download

Green circle

Preprint: archiving allowed

Upload

Orange circle

Postprint: archiving restricted

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO